| Literature DB >> 21798044 |
Catrine Tudor-Locke1, Cora L Craig, Yukitoshi Aoyagi, Rhonda C Bell, Karen A Croteau, Ilse De Bourdeaudhuij, Ben Ewald, Andrew W Gardner, Yoshiro Hatano, Lesley D Lutes, Sandra M Matsudo, Farah A Ramirez-Marrero, Laura Q Rogers, David A Rowe, Michael D Schmidt, Mark A Tully, Steven N Blair.
Abstract
Older adults and special populations (living with disability and/or chronic illness that may limit mobility and/or physical endurance) can benefit from practicing a more physically active lifestyle, typically by increasing ambulatory activity. Step counting devices (accelerometers and pedometers) offer an opportunity to monitor daily ambulatory activity; however, an appropriate translation of public health guidelines in terms of steps/day is unknown. Therefore this review was conducted to translate public health recommendations in terms of steps/day. Normative data indicates that 1) healthy older adults average 2,000-9,000 steps/day, and 2) special populations average 1,200-8,800 steps/day. Pedometer-based interventions in older adults and special populations elicit a weighted increase of approximately 775 steps/day (or an effect size of 0.26) and 2,215 steps/day (or an effect size of 0.67), respectively. There is no evidence to inform a moderate intensity cadence (i.e., steps/minute) in older adults at this time. However, using the adult cadence of 100 steps/minute to demark the lower end of an absolutely-defined moderate intensity (i.e., 3 METs), and multiplying this by 30 minutes produces a reasonable heuristic (i.e., guiding) value of 3,000 steps. However, this cadence may be unattainable in some frail/diseased populations. Regardless, to truly translate public health guidelines, these steps should be taken over and above activities performed in the course of daily living, be of at least moderate intensity accumulated in minimally 10 minute bouts, and add up to at least 150 minutes over the week. Considering a daily background of 5,000 steps/day (which may actually be too high for some older adults and/or special populations), a computed translation approximates 8,000 steps on days that include a target of achieving 30 minutes of moderate-to-vigorous physical activity (MVPA), and approximately 7,100 steps/day if averaged over a week. Measured directly and including these background activities, the evidence suggests that 30 minutes of daily MVPA accumulated in addition to habitual daily activities in healthy older adults is equivalent to taking approximately 7,000-10,000 steps/day. Those living with disability and/or chronic illness (that limits mobility and or/physical endurance) display lower levels of background daily activity, and this will affect whole-day estimates of recommended physical activity.Entities:
Mesh:
Year: 2011 PMID: 21798044 PMCID: PMC3169444 DOI: 10.1186/1479-5868-8-80
Source DB: PubMed Journal: Int J Behav Nutr Phys Act ISSN: 1479-5868 Impact factor: 6.457
Studies of free-living behaviour reporting percent meeting select step-defined cut points in older adults
| First Author | Sample Characteristics | Instrument | Monitoring Frame | Cut points used | % Meeting |
|---|---|---|---|---|---|
| Tudor-Locke [ | 6 men, 12 women; | Yamax Digiwalker SW-200, Yamax Corporation, Tokyo, Japan | 9 days | 10,000 | 50% never achieved 10,000 steps on any day of the monitoring frame |
| Newton [ | 54 women; | Actigraph MTI Health Services, USA | 6 days | Adult Graded Step Index | 24% > 10,000 |
| Rowe [ | 29 men, 60 women community dwelling | Yamax | 7 days | 10,000 | 9.6% of days > 10,000 |
| Ewald [ | 322 men, 362 women; | Yamax Digwalker SW-200 | 7 days | 8,000 [ | Overall: 42% > 8,000 |
Pedometer -based physical activity intervention studies with older adults
| Reference | Sample | Intervention duration; study duration and design | Instrument | Intervention Group | Intervention Group | Delta | Cohen's D |
|---|---|---|---|---|---|---|---|
| Conn [ | 65-96 years; community-dwelling; | 3-month intervention; 3-month randomized controlled trial | Yamax Digi-Walker | 2,773 ± 1,780 | 2,253 ± 1,394 | -520 | -0.33 |
| Croteau [ | 68-95 years; living in assisted living; 15 participants | 4-week intervention; 4-week quasi-experimental | Yamax Digi-Walker SW-200 | 3,031 ± 2,754 | 2,419 ± 2,296 | -612 | -0.24 |
| Jensen [ | 60-75 years; community -dwelling; 18 participants | 3-month intervention; 3-month quasi-experimental | Accusplit, San Jose, CA | 4,027 ± 2,515 | 5,883 ± 3,214 | 1,856 | 0.65 |
| Croteau [ | 60-90 year olds; | 4- month intervention; 4-month quasi-experimental | Accusplit AX120, San Jose, California | 4,041 ± 2,824 | 5,559 ± 3,866 | 1,518 | 0.45 |
| Croteau [ | 55-94 years; community-dwelling; 147 participants | 12-week intervention; 12-week quasi-experimental | Yamax Digi-Walker SW-200 (Yamax Corporation, Tokyo, Japan) | 4,963 | ≅ 6,200 | ≅ 1,237 | N/A |
| Sarkisian [ | ≥ 65 years; community-dwelling; 46 participants | 7-week intervention; 7-week quasi-experimental | Digiwalker (Yamax DW-500, New Lifestyles, Inc., Kansas City, MO) | 3,536 ± 2,280* | 4,387 ± 2,770* | 851 | 0.34 |
| Wellman [ | Mean 74.6 years; community-dwelling; 320 participants | 12-week intervention; 12-week quasi-experimental | NR | 3,110 ± 2,448 | 4,183 ± 3,257 | 1,073 | 0.38 |
| Rosenberg [ | 74-92 years; living in continuing care retirement community; 12 participants | 2 week intervention; 3-week quasi- experimental | Accusplit AH120M9, Pleasanton, CA | 3,020 ± 1,858 | 4,246 ± 2,331 | 1,226 | 0.59 |
| Culos-Reed [ | 46-83 years; community-dwelling; 39 participants | 8-week intervention; 8-week quasi-experimental | NR | 5,055 ± 1,374 | 5,969 ± 1,543 | 914 | 0.63 |
| Fitzpatrick [ | Mean 75 years; | 4-month intervention; 4-month quasi-experimental | Accusplit, San Jose, CA | 2,895 ± 2,170 | 3,743 ± 2,311 | 848 | 0.38 |
| Opdenacker [ | ≥ 60 years; community-dwelling; 46 intervention participants | 11-month intervention; 23-month randomized controlled trial | Yamax Digiwalker SW-200, Yamax Corporation, Tokyo, Japan | 7,390 ± 2,693** | 7,465 ± 3,344** | 75 | 0.02 |
| Sugden [ | 70-86 years; community-dwelling; | 12-week intervention; 12-week randomized controlled trial | Omron HJ-005 | 2,895 | NR | N/A | N/A |
| Koizumi [ | 60-78 years; community-dwelling; 34 intervention participants | 12-week intervention; 12-week randomized controlled trial | Kenz Lifecorder, Suzuken Company, Nagoya, Japan | 7,811 ± 3,268 | 9,046 ± 2,620 | 1,235 | 0.42 |
Steps/day presented as mean ± SD unless otherwise noted; *reported as steps/week in original article; divided by 7 days here; **SD calculated from reported SE
Pedometer - based physical activity intervention studies with special populations
| Reference | Sample | Intervention duration; study duration and design | Instrument | Intervention Group | Intervention Group | Delta | Cohen's D |
|---|---|---|---|---|---|---|---|
| Wilson [ | Adult breast cancer survivors; 22 intervention participants | 8-week intervention; | NR | 4,791 | 8,297 | 3,506 | N/A |
| Pinto [ | Adult breast cancer survivors; 43 intervention participants | 12-week intervention; 9-month randomized controlled trial | Intervention: pedometer (Yamax Digiwalker) | 4,471.7 ± 5,196.1 | 14,571.5 ± 9,489.5 | 10,100 | 1.38 |
| Vallance [ | Adult breast cancer survivors; 94 print materials, 94 pedometer only, 93 pedometer with print materials, 96 standard recommendation | 3-month intervention; 6-month randomized controlled trial | Digi-Walker SW-200 PED (New Lifestyles Inc., Lee's Summit, MO) | 8,476 ± 3,248 (Pedometer only) | 8,420 ± 5,226 (Pedometer only) | -210 | -0.06 |
| Irwin [ | Adults with early stage breast cancer; 37 intervention participants | 6-month intervention; 6-month randomized controlled trial | NR | 5,083 ± 2,313 | 6,738 ± 2,958 | 1,655 | 0.63 |
| Pinto [ | Breast cancer survivors; 25 intervention participants | 12-week intervention; 24-week quasi-experimental | Intervention: pedometer (Yamax Digiwalker) | No pre-intervention steps data reported but week one mean steps/day = 515.8 ± 470.8 | 1,695.4 ± 1,221.3 | 1,180 | 1.39 |
| Matthews [ | Breast cancer survivors; 13 intervention participants | 12-week intervention; 12-week randomized comparative trial | Intervention: pedometer (Brand NR) | 7,409.4 ± 2,791.1 | 8,561.8 ± 2887.3 | 1,152 | 0.41 |
| Blaauwbroek [ | Adult survivors of childhood cancer; 38 intervention participants | 10-week intervention; 36-week quasi-experimental | Yamax digiwalker SW-200 | 7,653 ± 3,272 | 11,803 ± 3,483 | 4,150 | 1.23 |
| Mustian [ | Mixed cancer type patients receiving radiation; 19 intervention participants | 4-week intervention; 3-month randomized controlled trial | NR | 7,222 ± 2,691 | 11,200 ± 5,851 | 3,978 | 0.93 |
| Swenson [ | Breast cancer patients receiving chemotherapy; 36 intervention participants (subsample of larger randomized trial) | 12- month intervention; 12-month quasi-experimental study conducted within a larger randomized trial | Walk 4 Life LS2500 (Walk 4 Life, Inc.) | No pre-intervention steps data reported but week one mean steps/day = 7,453 ± 2,519 | 9,429 ± 3,488 | 1,976 | 0.66 |
| Unweighted mean | 2,743 | 0.73 | |||||
| Weighted mean | 2,139 | 0.51 | |||||
| De Blok [ | Adults with COPD; 8 intervention participants | 9-week intervention; 9 week randomized controlled trial | Yamax Digi-Walker SW-200 (Tokyo, Japan) | 2,140 | 3,927 | 1,787 | N/A |
| Hopses [ | Adults with COPD; 18 intervention participants | 12-week intervention; 12-week randomized controlled trial | Digiwalker SW-2000 (Yamax, Tokyo, Japan) | 7,087 ± 4,058 | 7,872 ± 3,962 | 785 | 0.20 |
| Nguyen [ | Adults with COPD; 8 self-monitored (SM), 9 coached (C) | 6-month intervention; 6-month randomized comparative trial of cell-phone supported pedometer programs | Intervention: Omron HJ-112 (Omron Healthcare, Bannockburn, IL, USA) | SM: | SM: | SM: | SM: 0.02 |
| Unweighted mean | 541 | 0.02 | |||||
| Weighted mean | 562 | 0.06 | |||||
| VanWormer [ | Adults with coronary artery disease; 22 intervention participants | 17-week intervention; 17-week quasi-experimental | NR | 6,520.10 ± 2,926.99 | 8,210.24 ± 2,534.91 | 1,690 | 0.62 |
| Izawa | Adult myocardial infarction patients completing 6 months of cardiac rehabilitation; | 6-month intervention; 12-month randomized controlled trial | Kenz Lifecorder, (Suzuken, Nagoya, Japan) | 6,564.9 ± 1,114.6 | 10,458.7 ± 3,310.1 | 3,894 | 1.76 |
| Unweighted mean | 2,792 | 1.29 | |||||
| Weighted mean | 2,840 | 1.21 | |||||
| Tudor-Locke [ | Adults with type 2 diabetes; 9 intervention participants | 4-week intervention; 4-week quasi-experimental | Yamax Digiwalker SW-200 | 6,342 ± 2,244 | 10,115 ± 3,407 | 3,773 | 1.34 |
| Tudor-Locke [ | Adults with type 2 diabetes; 24 intervention participants | 16-week intervention; 24-week randomized controlled trial | Yamax SW-200, (Yamax Corporation, Tokyo, Japan) | 5,754 ± 2,457 | 9,123 ± 4,539 | 3,369 | 0.96 |
| Araiza [ | Adults with type 2 diabetes; 15 intervention participants | 6-week intervention; 6-week; randomized controlled trial | Yamax Digiwalker SW-701 (New Lifestyles, Kansas City, MI) | 7,220 ± 2792 | 10,410 ± 4,162 | 3,190 | 0.92 |
| Engel [ | Adults with type 2 diabetes; 30 coaching intervention, 24 pedometer intervention | 6-month intervention; 6-month randomized comparative trial | Yamax Digi-Walker-700 | NR | averaged 7,296 ± 2,066 during intervention | N/A | N/A |
| Richardson [ | Adults with type 2 diabetes; 17 lifestyle goals, 13 structured goals | 6-week intervention; | Omron HJ-720IT (beta test version) | Lifestyles goals: | Lifestyles goals: | Lifestyles goals: | Lifestyles goals: |
| Bjorgaas [ | Adults with type 2 diabetes; 19 intervention participants | 6-month intervention; | Yamax Dig-Walker ML AW-320, Yamax Corp, Tokyo, Japan | 7,628 ± 3,715 | 8,022 ± 3,368 | 394 | 0.11 |
| LeMaster [ | Adults with diabetic peripheral neuropathy; 41 intervention participants | 12-month intervention; | Intervention: Accusplit Eagle 170 (Pleasanton, CA) | 3,335 ± 1,575* | 3,183 ± 1,537* | -152 | -0.10 |
| Cheong [ | Adults with type 2 diabetes; 19 pedometer-only intervention (P); 19 pedometer and low glycemic index food intake intervention (PGI) | 16-week intervention; 16-week randomized comparative trial | NR | P: | P: | P: | P: |
| Johnson [ | Adults with type 2 diabetes; 21 Enhanced program, 17 Basic program | 12-week randomized comparative evaluation of two types of pedometer programs | Digi-Walker SW-200, (Yamax, Kyoto, Japan) | All participants: | All participants: | 1,685 | 0.44 |
| Kirk [ | Adults with type 2 diabetes; 42 in-person intervention (IP), | 6-month intervention; 12-month randomized controlled trial | ActiGraph GT1M (ActiGraph LLC, Pensacola, FL, USA) | IP: | IP: | IP: | IP: |
| Newton [ | Adolescents with type 1 diabetes; 34 intervention participants | 12-week intervention; 12-week randomized controlled trial | NR | Median 11,242 | Median 10,159 | N/A | N/A |
| Tudor-Locke [ | Adults with type 2 diabetes; 157 professional-led (PRO), 63 peer-led (PEER) participants | 16-week intervention; 16-week quasi-experimental comparison of program delivery | Yamax SW-200, (Yamax Corporation, Tokyo, Japan) | PRO: 3,980 ± 2,189 | PRO: | PRO: | PRO: |
| Vincent [ | Adults with type 2 diabetes; 9 intervention participants | 8-week intervention; 8-week randomized controlled trial | NR | 4,175 | 7,238 | 3,063 | N/A |
| De Greef [ | Adults with type 2 diabetes; 20 intervention participants | 12-week intervention, 12-week randomized controlled trial | Yamax DigiWalker SW200 | 7,099 ± 4,208 | 8,024 ± 5,331 | 925 | 0.19 |
| Diedrich [ | Adults with type 2 diabetes; 11 intervention participants | 3-month intervention; 3-month quasi-experiment | Yamax Digiwalker SW-200 | 4,145 ± 2,929*** | 6,486 ± 2,766*** | 2,341 | 0.82 |
| Unweighted mean | 2,061 | 0.65 | |||||
| Weighted mean | 2,405 | 0.78 | |||||
| Talbot [ | Adults with knee osteoarthritis; 17 walking plus education program | 12-week intervention; 12-week randomized comparative trial of a self-management education program with and without walking program | New Lifestyles Digi-walker SW-200 (Yamax, Tokyo, Japan) | 3,519 ± 2,603 | 4,337 ± 2,903 | 818 | 0.30 |
| Kilmer [ | Adults with neuromuscular disease; 20 intervention participants | 6-month intervention; 6-month quasi-experimental home-based activity and dietary intervention | NR | ≅ 4,600 (from figure) | ≅ 5,900 (from figure) | N/A | N/A |
| Fontaine [ | Adults with fibromyalgia syndrome; 14 intervention particpants | 12-week intervention; 12-week randomized comparative trial | Accusplit Eagle Activity Pedometer (San Jose, CA) | 2,337 ± 1,598* | 3,970 ± 2,238* | 1,633 | 0.85 |
| Unweighted mean | 1,226 | 0.57 | |||||
| Weighted mean | 1,186 | 0.55 | |||||
Note: Values are means ± SD unless otherwise stated, personal communication with Fontaine [120] clarified that what was reported in the published manuscript was actually SE; COPD = Chronic obstructive pulmonary disease; *SD calculated from reported SE; * post-test data obtained directly from corresponding author; ***reported as steps/week in original article, divided by 7 days here.
Figure 1Steps/day scale schematic linked to time spent in MVPA.